Skip to content

Main Navigation

Vor Bio
  • News & Media
  • Publications
  • Medical Professionals
  • Contact
  • Blog
  • Search
  • About Us
    • Overview
    • Vision, Mission, and Values
    • Our People
    • Leadership
    • Board of Directors
    • Scientific & Clinical Advisors
    • Founding Story
  • Approach
    • Overview
    • The Opportunity
    • The Concept
    • The Science
    • Programs
    • Manufacturing
    • Partnerships
  • Platform & Pipeline
    • Overview
    • Our Platform
    • Our Pipeline
  • Patients & Caregivers
    • Overview
    • What is AML?
    • Our Investigational Treatment Approach
    • Clinical Trials
    • The Patient/Donor Journey
    • Patient Advocacy
  • Join Us
    • Overview
    • Values & Culture
    • Benefits
    • Open Positions
    • Co-Op Program
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Contact IR
    • Email Alerts

News Topic: Vor’s first-in-human clinical trial of VBP101

September 9, 2024 by Erin Phelps

The Pharma Letter – Vor Bio plans pivotal trial following promising Phase I/II trial (Subscription Required)

Learn More
September 6, 2024 by Erin Phelps

BioWorld – Vor’s stem cell transplant delays cancer relapse (Subscription Required

Learn More
September 5, 2024 by Erin Phelps

STAT: Vor Biopharma’s ‘shielded’ transplant delays relapse in leukemia patients

Learn More
November 17, 2023 by Erin Phelps

Cell & Gene: Vor Bio Shares Progress For Patients with AML

Learn More
November 9, 2023 by Erin Phelps

Timmerman Report – Vor Bio Shows CRISPR’d Stem Cell Transplants Take Hold in AML Patients, Enable ADCs (Subscription Required)

Learn More
November 9, 2023 by Erin Phelps

Fierce Biotech – Vor Bio’s dual stem cell, ADC treatment shows consistent engraftment with reduced toxicity, but response data absent

Learn More
April 3, 2023 by Erin Phelps

Life Science Leader: Vor Bio’s Transition Into Clinical Trials

Learn More
February 16, 2023 by Jake Robison

Endpoints News: Putting a twist on targeted therapy, Vor Biopharma heralds proof of concept for its gene-edited stem cells

Learn More
January 18, 2023 by Jake Robison

Endpoints News: The conference is back. What about the industry? Taking the biotech pulse at #JPM23

Learn More

Posts navigation

  • 1
  • 2
  • »

Share This Post

Recent Vor Voices

  • A Legacy of Hope and Discovery April 10, 2025
  • Earning vs Deserving December 22, 2024
  • Satisfaction in Excellence November 24, 2024
  • Comfort is the Enemy? November 4, 2024
  • Remembering a Life and Embracing Hope: My Family’s Journey with AML and Our Fight for a Cure September 23, 2024
  • Understanding not just the jigsaw piece, but the entire puzzle September 10, 2024
  • Affinity vs Ability: Finding Work That Fits Your Personality August 23, 2024
  • Finding Joy in Work August 19, 2024
  • Fellowship in Action: Our First In-House Manufacturing Run June 26, 2024
Logo Vor Biopharma White

Follow us on social media:

Twitter LinkedIn Instagram

Boston Business Journal Badge 2023 2024
Read more about
working at Vor Bio

  • About Us
    • Vision, Mission, and Values
    • Our People
    • Leadership
    • Board of Directors
    • Scientific & Clinical Advisors
    • Founding Story
  • Approach
    • The Opportunity
    • The Concept
    • The Science
    • Programs
    • Manufacturing
    • Partnerships
  • Platform & Pipeline
    • Our Platform
    • Our Pipeline
  • Patients & Caregivers
    • What is AML?
    • Our Investigational Treatment Approach
    • Clinical Trials
    • The Patient/Donor Journey
    • Patient Advocacy
  • Medical Professionals
    • Our Investigational Programs
    • Clinical Trials
  • Investors
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Contact IR
    • Email Alerts
  • News & Media
  • Publications
  • Join Us
  • Blog

© 2025 Vor Bio

  • Privacy Policy
  • Terms of Use
Recruiting Guidelines

All employment opportunities at Vor Biopharma are managed by our in-house Human Resources Department. Therefore, agency staff and independent recruiters must contact the Human Resources Department directly in order to present candidates or inquire about openings. Please do not contact other Vor Bipharma employees. Your ability to comply with this request will significantly impact any decision we may make about doing business with you.

Please understand that we do not accept unsolicited resumes from any source other than from the candidates themselves. Any agency or independent recruiter must have a signed copy of our agency agreement before presenting candidates. Submission of unsolicited resumes without our signed agreement will not create any implied obligation on our part.

If you wish to be considered for the presentation of candidates, please contact us through careers@vorbio.com. Attach your contact information, your area of specialty, and any marketing information you wish to provide. Someone from the Human Resources Department will contact you directly if there is a business need for your services.